A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk

Dow Jones2025-12-30

0845 GMT - A merger between GSK and AstraZeneca could be a possibility given incoming GSK CEO Luke Miels's strong background and history with Astra CEO Pascal Soriot, Baader Europe analyst Abhishek Raval writes. Miels has worked closely with Soriot over the past ten years and there is no major overlap between the two companies' offerings, Raval says. With Soriot due to turn 67 next year, Astra might not have problems being lead by its current CEO's mentor, Raval writes. GSK shares have climbed 23% since late September, which Raval says could be linked to Miels's background leading big pharma. "In a nutshell, GSK's share price rally may still have more steam left," Raval writes. GSK shares are down 0.3% and Astra is down 0.1%. (ian.walker@wsj.com)

(END) Dow Jones Newswires

December 30, 2025 03:45 ET (08:45 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595760451?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595760451","market":"us","top_or_hot":-1,"title":"A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0845 GMT - A merger between GSK and AstraZeneca could be a possibility given incoming GSK CEO Luke Miels's strong background and history with Astra CEO Pascal Soriot, Baader Europe analyst Abhishek Raval writes. Miels has worked closely with Soriot over the past ten years and there is no major overlap between the two companies' offerings, Raval says. With Soriot due to turn 67 next year, Astra might not have problems being lead by its current CEO's mentor, Raval writes. GSK shares have climbed 23% since late September, which Raval says could be linked to Miels's background leading big pharma. \"In a nutshell, GSK's share price rally may still have more steam left,\" Raval writes. GSK shares are down 0.3% and Astra is down 0.1%. (ian.walker@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 30, 2025 03:45 ET (08:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-30 16:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0845 GMT - A merger between GSK and AstraZeneca could be a possibility given incoming GSK CEO Luke Miels's strong background and history with Astra CEO Pascal Soriot, Baader Europe analyst Abhishek Raval writes. Miels has worked closely with Soriot over the past ten years and there is no major overlap between the two companies' offerings, Raval says. With Soriot due to turn 67 next year, Astra might not have problems being lead by its current CEO's mentor, Raval writes. GSK shares have climbed 23% since late September, which Raval says could be linked to Miels's background leading big pharma. \"In a nutshell, GSK's share price rally may still have more steam left,\" Raval writes. GSK shares are down 0.3% and Astra is down 0.1%. (ian.walker@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 30, 2025 03:45 ET (08:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2417539215.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2595760451","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595760451","pubTimestamp":1767084300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0845 GMT - A merger between GSK and AstraZeneca could be a possibility given incoming GSK CEO Luke Miels's strong background and history with Astra CEO Pascal Soriot, Baader Europe analyst Abhishek Raval writes. Miels has worked closely with Soriot over the past ten years and there is no major overlap between the two companies' offerings, Raval says. With Soriot due to turn 67 next year, Astra might not have problems being lead by its current CEO's mentor, Raval writes. GSK shares have climbed 23% since late September, which Raval says could be linked to Miels's background leading big pharma. \"In a nutshell, GSK's share price rally may still have more steam left,\" Raval writes. GSK shares are down 0.3% and Astra is down 0.1%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4532":"文艺复兴科技持仓","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","GSK":"葛兰素史克","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","GSK.UK":"葛兰素史克","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股"},"translate_title":"葛兰素史克(GSK)与阿斯利康(AstraZeneca)合并可能是一种可能性——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5,"AZN":0.9,"GSK.UK":0.6},"content_text":"0845 GMT - A merger between GSK and AstraZeneca could be a possibility given incoming GSK CEO Luke Miels's strong background and history with Astra CEO Pascal Soriot, Baader Europe analyst Abhishek Raval writes. Miels has worked closely with Soriot over the past ten years and there is no major overlap between the two companies' offerings, Raval says. With Soriot due to turn 67 next year, Astra might not have problems being lead by its current CEO's mentor, Raval writes. GSK shares have climbed 23% since late September, which Raval says could be linked to Miels's background leading big pharma. \"In a nutshell, GSK's share price rally may still have more steam left,\" Raval writes. GSK shares are down 0.3% and Astra is down 0.1%. (ian.walker@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 30, 2025 03:45 ET (08:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595760451","isCrawlerRequest":true}